Session IV: Discussion DR. JOSEPH A. COTRUVO (U.S. EPA): If there is any occupation that is more frustrating than that of environmental epidemiologist, it must be that of a regulatory decision maker who must use environmental epidemiology study results as the basis for controversial decisions. Somehow the results are never conclusive, but rather "suggestive," yet the consequences of a decision one way or the other may be substantial. The problem is how to convert several pieces of equivocal data into regulatory policy. Not only the epidemiology but also the toxicology often leads to the same uncertainties that must be reasonably resolved.
If you have any doubts after listening to Dr. Calabrese and Dr. Cantor, let me suggest that you try going to the mayor of a small town in the Midwest, explaining to him that his water has excessive amounts of radium in it, and that he should try to reduce it. What do you tell him after he says "I have lived here 60 years and I have never seen anybody die of bone cancer"? Or, consider another mayor who has barium in his water and try to respond to his Congressman when he says "God put the barium in the water and no Federal agency is going to tell us to take it out." That's a direct quote! So the problems are great and the science is not all that clear. Nevertheless, decisions are necessary. We usually do not have the option of waiting for the next "definitive" study. The three papers in this session did an excellent job of pointing out a number of the strengths, weaknesses and complexities of environmental epidemiology.
I would distinguish between the first and the second two papers in that Dr. Enterline directly addressed occupational epidemiology. For all its problems, I think the situation is infinitely better there. At least there is the possibility of dealing with high doses, somewhat controlled populations, and perhaps there are greater opportunities to arrive at less equivocal conclusions. In the general environmental area (as opposed to occupational) all of the questions of controlling populations, looking for effects that may be very subtle, looking for exposures that may not be unique in those populations, and trying to control for all of the complicating variables generate a formidable task. Also, I would distinguish between the two sets of papers in the sense that the asbestos issue is one that is reasonably resolved. There is a consensus that a cause-effect relationship between inhalation of asbestos fibers and cancers of various sorts indeed exists. The question at this point is what is the standard to be, rather than if there really is a problem. Generally, that is not the situation in the environmental case. We are still arguing over the existence or lack of existence of health effects that a standard would purport to protect against in the general population. So, the issue is much less clear.
Relative to Dr. Enterline's statements, he made the very good point that we need to make some judgments about the practicality of conducting additional epidemiological studies in the area of interest. One has to do some very careful planning to determine, first of all, if additional epidemiologic data are necessary. Secondly, can studies in fact be designed that will lead to better understanding of the situation that exists? I would add, are those studies essential in order to select the final number for a standard? After all, once one has concluded that a substance is actually a human carcinogen at common exposure levels, the consensus, I believe, will argue for nonthreshold mechanisms and thus the lowest practical exposure. We are to a degree adding icing on the cake by trying to refine justifications beyond that point. Dr. Cantor talked about a number of studies that had been done, and I think his final concern was that EPA had made insufficient use of the epidemiology that was available at the time we wrote our drinking water standards for chloroform. I think we used it to the extent we could use it on its own merits, and on the interpretation of the National Academy of Science's Safe Drinking Water Committee. All of those studies were, in fact, quite preliminary, and in fact there were some conflicts among them. 
tion of positive results, some male, some female, some both, some not. For stomach cancer, about half are positive and half negative; not so many in the case of gastrointestinal cancer. We have to keep in mind that the studies were usually very preliminary. They did not control for many major factors, including smoking, in the vast majority of cases. As Dr. Cantor said, they were not quantitative, they were qualitative. We used them in that sense. We went to great lengths to discuss them in the standards. We rested our case on the toxicology, but stated that it was supported by the hypothesis generated by the epidemiology, and in fact, I will admit that the qualitative impetus for actually issuing the regulation at that time certainly was affected greatly by the existence of these studies. So they had a major impact on the decision process, even though they weren't necessarily used to produce the numbers. In closing, I would say that the problems are great in arriving at these decisions from available data, the science is complex and not clear in its interpretation. I would add my voice to the chorus I heard at this meeting, and also one that I attended last week on disinfection and risks, which is that obviously epidemiologists, toxicologists and clinicians really must get together. There is a great need for the marriage of all of those techniques, and to my mind future research should concentrate on the types of studies that do involve actual collection of physical, biological, and clinical data, whenever that is possible. Ex- As an administrative or organizational change, there may well be a shakedown period to assure that the appropriate kinds of interaction between Federal agencies develop. But given that all the Federal agencies are likely to be changed in the next couple of years, we had better make sure we know how we want to get epidemiology studies done, when organizational rearrangements are occurring.
DR. PETER INFANTE (OSHA): I have a question for Dr. Calabrese. You mentioned during your presentation that you testified as an expert witness for OSHA on the subject of an aromatic amine, where there was evidence in experimental animals, but no evidence in humans of some kind of adverse effect, or potential for an adverse effect. Subsequently I understood you to make a comment that public health decisions should be based on epidemiologic data. It is this latter comment on which I am asking for some clarification. Were you talking about substances that were not carcinogens, or were you including carcinogens in that statement also? Were you talking about sodium or some other things? DR. CALABRESE: I was referring to a much more general approach, and in this particular case, I really hadn't limited it to either noncarcinogenic or carcinogenic outcomes. Clearly if one is to make some type of statement with respect to setting standards, it is important to get information from whatever sources are available.
In terms of scientific certainty, both animal experimentation and epidemiological research complement one another in attempting to resolve the scientific issue DR. COTRUVO: What you say is correct on the issue of having sufficient studies from which to make these regulatory decisions; and the fact that there are pressures on the other side not to regulate. Ifthere is a credible epidemiologic study that permits the conclusion that there is real risk involved, then I think society gets mobilized, decisions are made and reductions of exposure are incurred. History shows that. So I don't think that is the problem. The problem arises when there is a lot of uncertainty, both on the scientific side and on the economic side. I agree with you that economics isn't necessarily any more precise than biomedical science.
There are shifts in philosophy that occur with time. Maybe five years ago the philosophy was very strongly in a protective direction, and maybe now it is a little less so in some quarters. The point is, if the case is good, it will carry. I wish there were a lot of targets of opportunity that will answer a lot of these questions at low cost. I wonder why they didn't occur in the last five years and why will they begin to appear now.
The problems are great and complicated, and there are not easy answers. But I repeat, it is still ultimately economics that controls regulatory decisions, whether there are precise analytical predictors of effects or not. The cost-benefit equation is tilted one way or another based on the strength of the science to induce the change.
